BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22136862)

  • 1. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
    Oliveira A; Lobo I; Alves R; Lima M; Selores M
    Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
    Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
    Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Sézary syndrome].
    Ferreira F; Correia TM; Callabro L; Andrade J
    Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sezary syndrome.
    Ali CM; Sikdar TK; Sultana N; Hoque MR; Ahmed N; Parvez Z; Kamal B; Rahman F
    Mymensingh Med J; 2011 Jul; 20(3):497-500. PubMed ID: 21804519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sézary syndrome presenting with 'leonine facies'.
    Nassem S; Kashyap R; Awasthi NP; Krishnani N; Kumari N
    Australas J Dermatol; 2009 Nov; 50(4):285-8. PubMed ID: 19916974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Malignant lymphoma of the skin].
    Nakajima H; Miyamoto H
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1735-43. PubMed ID: 3876074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab in Sézary syndrome: efficient but not innocent.
    Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
    Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folliculotropic mycosis fungoides and a leonine clinical appearance of the face.
    Ito T; Yamamoto T; Matsumoto Y; Wakamatsu J; Kato Y; Tsuboi R
    Dermatol Online J; 2008 Sep; 14(9):6. PubMed ID: 19061588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leonine facies due to Sezary syndrome: complete clinical, radiologic, and molecular remission with alemtuzumab.
    Kho B; Wong HHN; Sin CF; Leung RYY; Kwong YL
    Ann Hematol; 2017 Dec; 96(12):2121-2123. PubMed ID: 28828693
    [No Abstract]   [Full Text] [Related]  

  • 12. Alemtuzumab in refractory Sézary syndrome.
    Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
    An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained remission of Sézary syndrome.
    Bouwhuis SA; McEvoy MT; Davis MD
    Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A patient with erythroderma and pruritus: Sézary syndrome].
    Overweel AFP; Langerak AW; Damman J; de Haas ELM; Weerkamp F; Sandberg Y
    Ned Tijdschr Geneeskd; 2022 Feb; 166():. PubMed ID: 35499588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
    Fernandes IC; Gonçalves M; dos Anjos Teixeira M; Gonçalves C; Coutinho J; Selores M; Alves R; Lima M
    J Am Acad Dermatol; 2012 Nov; 67(5):1083-5. PubMed ID: 23062898
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of pre-Sézary syndrome preceded by hand lesions.
    Lee NH; Lee SW; Choi EH; Lee WS; Ahn SK
    J Dermatol; 1999 Jul; 26(7):465-8. PubMed ID: 10458089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
    Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
    Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
    [No Abstract]   [Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
    Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
    Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
    el-Azhary RA; Bouwhuis SA
    Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular Sézary syndrome with bullous lesions on the feet.
    Dehesa L; Bastida J; Camacho-Galán R; Campos-Adsuar C; Gómez-Duaso J; Vilar-Alejo J
    Eur J Dermatol; 2009; 19(3):282-3. PubMed ID: 19258239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.